<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Chemistry</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5A4EC0AB-C3B1-4909-BDD4-C987C9CDE161"><gtr:id>5A4EC0AB-C3B1-4909-BDD4-C987C9CDE161</gtr:id><gtr:firstName>Jason</gtr:firstName><gtr:surname>Micklefield</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2E823DAA-1E49-462C-8CC5-C6263A3E2364"><gtr:id>2E823DAA-1E49-462C-8CC5-C6263A3E2364</gtr:id><gtr:firstName>Finbarr</gtr:firstName><gtr:surname>Hayes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/84EEDF95-CDEF-423A-B6F3-B184BE811A13"><gtr:id>84EEDF95-CDEF-423A-B6F3-B184BE811A13</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Edward</gtr:otherNames><gtr:surname>McCarthy</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FD005612%2F1"><gtr:id>D40EFB4A-D4EA-4049-A7F6-C864E435312D</gtr:id><gtr:title>Co-evolution of small molecule responsive riboswitches</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/D005612/1</gtr:grantReference><gtr:abstractText>Small molecule modulators of gene expression, which offer rapid, temporal and spatial control of gene expression, would be tremendously valuable tools in biological and biomedical sciences. Indeed there are relatively few examples of small molecule-inducible expression systems that are available for general use. In addition, the ability to control differentially the expression of multiple genes simultaneously, using distinct small molecule inhibitors or inducers, remains extremely limited. In this project we aim to engineer new regulatory systems that function in prokaryotic and eukaryotic cells and respond in a rapid dose-dependent fashion to a wide range of small drug-like molecules. It is envisaged that the ability to control gene expression in response to a wide range of small molecule could lead to many profound applications in pharmaceutical target validation, gene therapy, bioremediation, biosensors, and plant biotechnology.</gtr:abstractText><gtr:technicalSummary>Small molecule modulators of gene expression, which offer rapid, temporal and spatial control of gene expression, would be tremendously valuable tools in biological and biomedical sciences. Indeed there are relatively few examples of small molecule-inducible expression systems that are available for general use. In addition, the ability to control differentially the expression of multiple genes simultaneously, using distinct small molecule inhibitors or inducers, remains extremely limited. In this project we aim to engineer new regulatory systems that function in prokaryotic and eukaryotic cells and respond in a rapid dose-dependent fashion to a wide range of small drug-like molecules. It is envisaged that the ability to control gene expression in response to a wide range of small molecule could lead to many profound applications in pharmaceutical target validation, gene therapy, bioremediation, biosensors, and plant biotechnology.</gtr:technicalSummary><gtr:fund><gtr:end>2010-09-15</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2006-05-16</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>688479</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>146000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Feasibility and Benchmarking of RiboTite gene expression control technology</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/J019089/1</gtr:fundingRef><gtr:id>2F8C0C2D-E323-4552-B016-079FB32A9C05</gtr:id><gtr:outcomeId>5ee558325ee55846</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>see final report submitted to bbsrc</gtr:description><gtr:id>081CBF83-5D60-4877-97D2-2C5E08F9CC25</gtr:id><gtr:impactTypes/><gtr:outcomeId>5463878dab3b76.62382334</gtr:outcomeId></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Dixon, N.; Micklefield, J.
Riboswitch-regulated transgene expression systems
From PCT Int. Appl.&amp;nbsp;(2012),&amp;nbsp;WO&amp;nbsp;2012153142&amp;nbsp;A2&amp;nbsp;20121115. &amp;nbsp;</gtr:description><gtr:grantRef>BB/D005612/1</gtr:grantRef><gtr:id>6B130F1B-B7F6-4420-9EB1-0E54775A2858</gtr:id><gtr:impact>Dixon, N.; Micklefield, J.
Riboswitch-regulated transgene expression systems
From PCT Int. Appl. (2012), WO 2012153142 A2 20121115.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>m-8998792431.316145766799fa</gtr:outcomeId><gtr:patentId>WO2012153142</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Riboswitch-regulated transgene expression systems</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>We successfully re-engineered the first orthogonal riboswitches, which no longer respond to the natural cellular metabolites, and can be used to activate gene expression in a precise dose-dependent fashion with a variety of synthetic ligands not present within the cell. We have characterised these riboswitches in vivo and in vitro using ITC, SHAPE and X-ray crystallography, producing the first high-resolution structure of an orthogonal riboswitch in complex with a synthetic ligand. A full report detailing all of the outcomes of this research has been submitted to BBSRC and only key publications and patents are listed here.</gtr:description><gtr:exploitationPathways>This application of the orthogonal riboswitch technology is probably best realised through collaboration with established companies who develop protein expression systems, vectors and expression hosts etc. A patent application has been submitted and development work, supported by BBSRC follow-on-funding, is underway to explore the potential applications of orthogonal riboswitches for protein expression etc.</gtr:exploitationPathways><gtr:id>BAC92B51-52BB-4B44-A7E1-CCDE3B8B84A7</gtr:id><gtr:outcomeId>r-4613925790.985977777044c0</gtr:outcomeId><gtr:sectors><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6AADDDE1-8299-4353-B55F-C41E6D1B7325</gtr:id><gtr:title>Orthogonal riboswitches for tuneable coexpression in bacteria.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b80e99cdfc94ebd78a35562fdafe3de3"><gtr:id>b80e99cdfc94ebd78a35562fdafe3de3</gtr:id><gtr:otherNames>Dixon N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>5462410d1a0142.46755644</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4E46F1F-E4CF-42F5-BE9E-353822D9AF4E</gtr:id><gtr:title>Generation of orthogonally selective bacterial riboswitches by targeted mutagenesis and in vivo screening.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23690bee8bb4b9c5c4c98396af52bad9"><gtr:id>23690bee8bb4b9c5c4c98396af52bad9</gtr:id><gtr:otherNames>Vincent HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>978-1-62703-754-9</gtr:isbn><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>546245a7b219e8.66863530</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC771FD5-34BD-475D-84DF-83AA40898A9E</gtr:id><gtr:title>Reengineering orthogonally selective riboswitches.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b80e99cdfc94ebd78a35562fdafe3de3"><gtr:id>b80e99cdfc94ebd78a35562fdafe3de3</gtr:id><gtr:otherNames>Dixon N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_5435a9e5a9ea6057f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>863328E8-5E6E-4886-9811-4549A2D4A61C</gtr:id><gtr:title>Probing riboswitch-ligand interactions using thiamine pyrophosphate analogues.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbfd9fb6e692d07596464ca94848bf67"><gtr:id>fbfd9fb6e692d07596464ca94848bf67</gtr:id><gtr:otherNames>Chen L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>pm_5435a9e5a9e9b0d78</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/D005612/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>